Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Article Menu
Export Article
More by Authors Links
Article Data
- Views 2060
- Dowloads 119
Case Reports
Open AccessAdvanced stage yolk sac ovarian tumour: clinical approach with cytoreductive surgery upfront
Advanced stage yolk sac ovarian tumour: clinical approach with cytoreductive surgery upfront
1Medical Oncology Department, Centro Hospitalar São João, Porto, Portugal, Spain
2Medical Oncology Department, MD Anderson Cancer Center, Madrid, Spain
3Department of Pathology, MD Anderson Cancer Center, Madrid, Spain
4Department of Gynecology, MD Anderson Cancer Center, Madrid, Spain
*Corresponding Author(s): I. Pimentel E-mail: immpsp@gmail.com
Abstract
The authors report the case of a 21-year-old woman that presented a Pseudo Meigs’ syndrome, secondary to a pure endodermal sinus tumour (yolk sac tumour). Fine needle aspiration biopsy was compatible with high-grade carcinoma and the alpha fetoprotein (αFP) was at 13,185 U/ml. Cytoreductive surgery was performed, followed by bleomycin, etoposide, and cisplatin (BEP) chemotherapy.
Keywords
Yolk sac ovarian tumour; Endodermal sinus ovarian tumour.
Cite and Share
I. Pimentel,A. González Martín,R. Bratos,R. Marquez,G. Toledo,L. Chiva. Advanced stage yolk sac ovarian tumour: clinical approach with cytoreductive surgery upfront. European Journal of Gynaecological Oncology. 2017. 38(2);311-313.
References
[1] DeVita V., Lawrence T., Rosenberg S.: “Principles and Practice of Oncology”. 9thed. Philadelphia: Lippincott Williams & Wilkins, 2011 104, 1386.
[2] Fujita M., Inoue M., Tanizawa O., Minagawa J., Yamada T., Tani T.: “Retrospective review of 41 patients with endodermal sinus tumor of the ovary”. Int. J. Gynecol Cancer, 1993, 3, 329.
[3] Wu P.C., Huang R.L., Lang J.H., Huang H.F., Lian L.J., Tang M.Y.: “Treatment of malignant ovarian germ cell tumors with preservation of fertility: a report of 28 cases”. Gynecol. Oncol., 1991, 40, 2.
[4] Dällenbach P., Bonnefoi H., Pelte M.F., Vlastos G.: “Yolk sac tumours of the ovary: an update”. Eur. J. Surg. Oncol., 2006, 32, 1063.
[5] Berman M.L.: “Future directions in the surgical management of ovarian cancer”. Gynecol. Oncol., 2003, 90, 33.
[6] Pectasides D., Pectasides E., Kassanos D.: “Germ cell tumors of the ovary” Cancer Treat. Rev., 2008, 34, 427.
[7] Kazanov L., Ander D.S., Enriquez E., Jaggi F.M.: “Pseudo-Meigs’ syndrome”. Am. J. Emerg. Med., 1998, 16, 404.
[8] Williams S., Blessing J.A., Liao S.Y., Ball H., Hanjani P.: “Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide and bleomycin: a trial of the Gynecology Oncology Group”. J. Clin. Oncol., 1994, 12, 701
[9] Lee C.W., Song M.J.., Park S.T., Ki E.Y., Lee S.J., Lee K.H., et al.: “Residual tumor after the salvage surgery is the major risk factors for primary treatment failure in malignant ovarian germ cell tumors: A retrospective study of single institution”. World J. Surg, Oncol., 2011, 9, 123.
[10] Nawa A., Obata N., Kikkawa F., Kawai M., Nagasaka T., Goto S., et al.: “Prognostic factors of patients with yolk sac tumors of the ovary”. Am. J. Obstet. Gynecol., 2001, 184, 1182.
[11] Kawai M., Kano T., Furuhashi Y., Mizuno K., Nakashima N., Hattori S.E., et al.: “Prognostic factors in yolk sac tumors of the ovary. A clinicopathologic analysis of 29 cases”. Cancer, 1991, 67, 184.
[12] Gershenson D.M., Morris M., Cangir A., Kavanagh J.J, Stringer C.A., Edwards C.L., et al.: “Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin”. J. Clin. Oncol., 1990, 8, 715.
[13] Gershenson D.M.: “Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors”. J. Clin. Oncol., 1988, 6, 270.
[14] Mitchell P.L., Al-Nasiri N., A’Hern R., Fisher C., Horwich A., Pinkerton C.R., et al.: ” Treatment of non-dysgerminomatous ovarian germ cell tumors: an analysis of 69 cases”. Cancer, 1999, 85, 2232.
Submission Turnaround Time
Top